Study #2023-0579
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG 509 in subjects with metastatic castration-resistant Prostate Cancer
MD Anderson Study Status
Enrolling
Treatment Agent
AMG 509, Abiraterone, Enzalutamide
Description
The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amendment 10 (09 July 2025), only Parts 4A expansion, 6, and 7 are open to accrual.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Prostate Cancer
Study phase:
Phase I
Physician name:
Bilal Siddiqui
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.